Insider Selling: Cryoport, Inc. (NASDAQ:CYRX) CEO Sells 4,620 Shares of Stock

Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 4,620 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the sale, the chief executive officer now directly owns 765,399 shares of the company’s stock, valued at $4,814,359.71. This trade represents a 0.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jerrell Shelton also recently made the following trade(s):

• On Monday, March 10th, Jerrell Shelton sold 4,173 shares of Cryoport stock. The shares were sold at an average price of $4.88, for a total transaction of $20,364.24.

Cryoport Trading Down 4.9 %

Shares of NASDAQ:CYRX traded down $0.32 on Tuesday, hitting $6.17. The company had a trading volume of 728,831 shares, compared to its average volume of 534,310. The firm’s 50-day simple moving average is $6.98 and its two-hundred day simple moving average is $7.43. Cryoport, Inc. has a 1 year low of $4.58 and a 1 year high of $20.11. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $307.94 million, a price-to-earnings ratio of -1.83 and a beta of 1.67.

Cryoport (NASDAQ:CYRX) last posted its earnings results on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The company had revenue of $59.53 million during the quarter, compared to analysts’ expectations of $58.71 million. During the same period in the prior year, the business posted ($0.29) earnings per share. Equities analysts anticipate that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cryoport

Several institutional investors and hedge funds have recently modified their holdings of CYRX. Thematics Asset Management lifted its position in shares of Cryoport by 176.2% in the 3rd quarter. Thematics Asset Management now owns 1,705,000 shares of the company’s stock worth $13,828,000 after purchasing an additional 1,087,800 shares during the period. Fred Alger Management LLC lifted its position in Cryoport by 49.9% during the 3rd quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company’s stock valued at $21,887,000 after acquiring an additional 898,481 shares during the period. Cadian Capital Management LP lifted its position in Cryoport by 14.1% during the 4th quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company’s stock valued at $38,332,000 after acquiring an additional 609,021 shares during the period. Point72 Asset Management L.P. purchased a new position in Cryoport during the 3rd quarter valued at about $3,405,000. Finally, Millennium Management LLC lifted its position in Cryoport by 11.0% during the 4th quarter. Millennium Management LLC now owns 4,139,869 shares of the company’s stock valued at $32,208,000 after acquiring an additional 409,353 shares during the period. 92.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CYRX has been the subject of a number of recent analyst reports. Guggenheim initiated coverage on shares of Cryoport in a report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Cryoport in a report on Wednesday, March 5th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.